Trial Profile
A retrospective cohort study of patients with chronic myelogenous leukemia receiving dasatinib or nilotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2019
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 13 Jul 2016 New trial record